Introduction {#sec1-0300060519863190}
============

Endometrial cancer (EC) is the second most prevalent gynecological malignancy in China according to the National Central Cancer Registry of China, with a 5-year prevalence rate of 31.6 per 100,000 women.^[@bibr1-0300060519863190]^ Current treatment strategies for EC are based on the International Federation of Gynecologists and Obstetricians (FIGO) staging system. The 1988 FIGO staging system defined stage II EC as EC with cervical mucosal and stromal involvement; however, the 2009 revised staging criteria indicated that stage II EC should only include patients with cervical stromal invasion.^[@bibr2-0300060519863190]^ Radical hysterectomy (RH) with bilateral salpingo-oophorectomy (BSO) is recommended for patients with stage II EC on the basis of the 2014 European Society for Medical Oncology (EMSO) and National Comprehensive Cancer Network (NCCN) guidelines.^[@bibr3-0300060519863190][@bibr4-0300060519863190]--[@bibr5-0300060519863190]^ However, recently published NCCN guidelines for uterine neoplasms in 2018 recommend both simple hysterectomy (SH) and RH for operable patients with cervical involvement, together with BSO, cytology (peritoneal lavage), and lymph node dissection if indicated.^[@bibr6-0300060519863190]^ In addition, the latest ESMO guidelines do not recommend RH for the management of stage II EC, and the recommendation is for EC up to grade B.^[@bibr7-0300060519863190]^

RH refers to excision of the uterus with the parametrium (i.e., round, broad, cardinal, and uterosacral ligaments) and the upper one-third to one-half of the vagina. However, stage II EC does not invade the parametrium or vagina. Furthermore, RH is associated with a high postoperative incidence of sexual dysfunction, significant blood loss, bladder and bowel dysfunction, and fistula formation.^[@bibr8-0300060519863190],[@bibr9-0300060519863190]^ Nevertheless, several clinical studies have demonstrated the benefits of RH compared with SH in patients with stage II EC, and showed that RH or modified RH might improve overall survival compared with SH.^[@bibr10-0300060519863190][@bibr11-0300060519863190]--[@bibr12-0300060519863190]^ However, other studies have provided contradictory results, and showed that SH provided comparable survival outcomes to RH in patients with FIGO stage II EC.^[@bibr13-0300060519863190][@bibr14-0300060519863190]--[@bibr15-0300060519863190]^ Therefore, despite changes in the guidelines, the need for more invasive surgical methods for stage II EC remains controversial.

We aimed to address this controversy and the validity of the changes in the guidelines by examining previous articles published over several decades, and by comparing the survival and perioperative outcomes of matched patients with stage II EC who underwent SH or RH at the Obstetrics and Gynecology Hospital of Fudan University.

Materials and methods {#sec2-0300060519863190}
=====================

Study selection for literature review {#sec3-0300060519863190}
-------------------------------------

We screened studies investigating survival outcomes of patients with stage II EC treated with SH or RH worldwide over several decades. We performed a MEDLINE search with the keywords *simple hysterectomy, radical hysterectomy, stage II endometrial cancer*, and *survival*. We also further searched the reference lists of relevant publications to identify missed studies.

Study participants {#sec4-0300060519863190}
------------------

A total of 1171 patients were diagnosed with EC and operated on at the Obstetrics and Gynecology Hospital of Fudan University from 2000 to 2014. Patients with pathological stage II EC according to the FIGO 2009 guidelines were included in the study. Patients with only cervical glandular invasion and patients who were lost to follow-up were excluded. The remaining patients were divided into an RH and SH group, matched according to age, pathological type, and lymphovascular space invasion (LVSI) using a case-matching method. BSO, lymphadenectomy, omentum resection, and appendectomy were performed as appropriate. Patients were under observation or received subsequent therapy, including chemotherapy, radiotherapy, or endocrine therapy, if necessary. Demographic, surgical, pathological, and postoperative outcome data were extracted from the resident admission notes, discharge records, surgical records, pathology reports, progress notes, and nursing records in the medical archives of the Obstetrics and Gynecology Hospital of Fudan University. Information on patient outcomes was obtained by telephone follow-up at specified intervals. The study was approved by the ethics committee of the Obstetrics and Gynecology Hospital of Fudan University. All enrolled patients provided written informed consent.

Surgical methods {#sec5-0300060519863190}
----------------

SH involved complete removal of the uterus and cervix, with or without BSO, and RH involved additional resection of the lateral parametrium and ventral parametrium. RH was further classified into four types according to the range of parametrial resection, based on criteria published in 2011.^[@bibr16-0300060519863190]^ All types of RH, except type 4, met the study inclusion criteria.

Performance of lymphadenectomy associated with SH or RH, as well as omentum resection, was decided based on pre- and perioperative findings.

Statistical analysis {#sec6-0300060519863190}
--------------------

Categorical and numerical demographic, surgical, pathological, and postoperative variables in the SH and RH groups were analyzed and compared using χ^2^ and *t*-tests. *P* \< 0.10 or *P* \< 0.05 was considered to indicate statistical significance.

The main outcome was cancer-related survival, with death as an event. Survival was compared using the log-rank test and Kaplan--Meier analysis. Multivariate analysis was carried out by Cox proportional hazards regression.

Results {#sec7-0300060519863190}
=======

Previous studies of survival following SH and RH for stage II EC {#sec8-0300060519863190}
----------------------------------------------------------------

A search of the MEDLINE database for studies of patients with stage II EC treated with SH or RH identified 11 relevant articles published from 1993 to 2017. Three articles were based on data from the Surveillance, Epidemiology, and End Result (SEER) database, and the other eight were retrospective studies from America, Italy, Turkey, and Japan. There was thus a lack of data from China in relation to survival after SH and RH among patients with stage II EC. All four studies conducted before 2011 showed that survival after RH was superior to that after SH, while all five studies conducted after 2009 showed similar survival after RH and SH ([Table 1](#table1-0300060519863190){ref-type="table"}). These results suggest that the survival advantage of RH in patients with stage II EC gradually disappeared, and the procedure may have resulted in more serious perioperative complications. In addition, studies from America and Italy found that survival after RH was superior to that after SH, while studies from Turkey and Japan found similar survival after RH and SH ([Table 1](#table1-0300060519863190){ref-type="table"}). The conclusions regarding the relative outcomes of RH and SH may thus be affected by both geographic region and study period.

###### 

Summary of previous articles comparing survival of patients with stage II endometrial cancer following SH or RH.

![](10.1177_0300060519863190-table1)

  Author                                          Publication year   Study period   Region          Sample size   Survival (SH vs RH)
  ----------------------------------------------- ------------------ -------------- --------------- ------------- ---------------------------------------------------
  Boente et al.^[@bibr26-0300060519863190]^       1993               1972--1988     USA             202           RH superior to SH(77% vs 86%)5 year-related OS
  Cornelison et al.^[@bibr12-0300060519863190]^   1999               1988--1994     SEER database   932           RH superior to SH(84% vs 92.96%)5 year-related OS
  Mariani et al.^[@bibr27-0300060519863190]^      2001               1984--1993     Italy           82            RH superior to SH(68% vs 76%)5 year-related OS
  Sartori et al.^[@bibr10-0300060519863190]^      2001               1980--1995     Italy           203           RH superior to SH(79% vs 94%)5 year-related OS
  Ayhan et al.^[@bibr28-0300060519863190]^        2004               1982--2000     Turkey          48            RH equal to SH(83% vs 90%)5 year-related OS
  Cohn et al.^[@bibr11-0300060519863190]^         2007               1982--2004     USA             162           RH superior to SH(81% vs 88%)5 year-related OS
  Wright et al.^[@bibr29-0300060519863190]^       2009               1988--2004     SEER database   1577          RH equal to SH(79% vs 82%)5 year-related OS
  Miyamoto et al.^[@bibr30-0300060519863190]^     2016               1990--2009     Japan           247           RH equal to SH
  Phelippeau and Koskas^15^                       2016               1998--2012     SEER database   819           RH equal to SH(88.7% vs 94.1%)3 year-related OS
  Takano et al.^[@bibr13-0300060519863190]^       2013               1995--2009     Japan           300           RH equal to SH(84% vs 83.6%)5 year-related OS
  Ozgul et al.^[@bibr14-0300060519863190]^        2018               2002--2015     Turkey          250           RH equal to SH(83% vs 89%)5 year-related OS

SH: simple hysterectomy, RH: radical hysterectomy, OS: overall survival.

Patient characteristics {#sec9-0300060519863190}
-----------------------

Among 1171 patients diagnosed with EC and operated on from 2000 to 2014, 155 women aged 23 to 77 years were diagnosed with stage II EC according to final pathology reports during the same period. Of these 155 patients, 56 had undergone SH and 99 had undergone RH. Sixteen of these 155 patients died of tumor recurrence but no patients died of other causes during the follow-up period. We excluded 30 patients who were lost to follow-up (11 SH and 19 RH). Following case-matching, 80 patients (40 SH and 40 RH) were therefore included in our final study ([Figure 1](#fig1-0300060519863190){ref-type="fig"}). The demographic, surgical, and pathological characteristics of the patients are presented in [Table 2](#table2-0300060519863190){ref-type="table"}.

![Flowchart of case selection in matched-pair analysis. A case-matched method was used to obtain two homogeneous groups according to age, pathological type, and LVSI. EC: endometrial cancer, SH: simple hysterectomy, RH: radical hysterectomy, LVSI: lymphovascular space invasion.](10.1177_0300060519863190-fig1){#fig1-0300060519863190}

###### 

Patient demographic, surgical, and pathological characteristics.

![](10.1177_0300060519863190-table2)

                                                    Simplehysterectomy   Radical hysterectomy   χ^2^*P* value
  ------------------------------------------------- -------------------- ---------------------- ---------------
  Age (years)                                       52.75 ± 9.32         52.80 ± 9.44           0.981
  Pathological type                                                                             
   Endometrioid adenocarcinoma                      30                   29                     0.800
   Other type^\*^                                   10                   11                     
  Grade (among endometrioid adenocarcinomas)                                                    
   1                                                18                   9                      0.072
   2                                                10                   15                     
   3                                                2                    5                      
  Tumor size according to final pathologic record                                               
   \<2 cm                                           16                   8                      0.137
   2--5 cm                                          17                   21                     
   \>5 cm                                           7                    11                     
  Myometrial invasion depth                                                                     
   \<1/2                                            27                   26                     0.813
   ≥1/2                                             13                   14                     
  Cervical stromal invasion depth                                                               
   \<1/2                                            33                   28                     0.293
   ≥1/2                                             7                    12                     
  LVSI                                                                                          
   No                                               32                   28                     0.302
   Yes                                              8                    12                     
  Hypertension                                                                                  
   No                                               31                   33                     0.576
   Yes                                              9                    7                      
  Diabetes                                                                                      
   No                                               33                   34                     0.762
   Yes                                              7                    6                      
  Surgical pathway                                                                              
   Laparotomy                                       21                   23                     0.186
   Laparoscopic surgery                             19                   17                     
  Lymphadenectomy                                                                               
   No                                               6                    2                      0.136
   Yes                                              34                   38                     
  Omentum resection                                                                             
   No                                               36                   38                     0.396
   Yes                                              4                    2                      
  Postsurgical treatment                                                                        
   Observation                                      16                   16                     0.506
   Chemotherapy                                     17                   17                     
   Chemotherapy+radiotherapy                        7                    5                      
   Endocrine therapy                                0                    2                      

\*Serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and mixed cell adenocarcinoma. LVSI: lymphovascular space invasion.

The groups were comparable with regard to age, pathological type, pathological grade, tumor size, depth of myometrial invasion, depth of cervical stromal invasion, LVSI, hypertension, diabetes, surgical pathway, postoperative therapy, lymphadenectomy, and omentum resection.

Three patients (3/40, 7.5%) in the SH group had recurrence, including one in the pelvis, one in the liver, and one in the liver, pelvis, and intestines. Four patients (4/40, 10%) in the RH group had recurrence, including one in the vaginal cuff, two in the pelvis, and one with distant metastasis in the liver.

Survival of patients with stage II EC {#sec10-0300060519863190}
-------------------------------------

The relationships between demographic, surgical, and pathological factors and overall survival were assessed by Kaplan--Meier analysis, which identified primary tumor pathological type (*P* = 0.069), LVSI (*P* = 0.063), surgical pathway (*P* = 0.059), and lymphadenectomy (*P* = 0.041) as significant predictors of overall survival ([Table 3](#table3-0300060519863190){ref-type="table"}). These significant prognostic factors (*P* \< 0.100) in the Kaplan--Meier analysis were then analyzed using a Cox proportional hazards model. However, after removing confounding factors, no factor had any significant effect on survival of patients with stage II EC ([Table 4](#table4-0300060519863190){ref-type="table"}).

###### 

Prognostic indicators in patients with stage II endometrial cancer.

![](10.1177_0300060519863190-table3)

  Risk factor                                  Cases   Deaths   Cancer-related survival rate   χ^2^    *P*
  -------------------------------------------- ------- -------- ------------------------------ ------- -------
  Age (years)                                                                                          
   \<60                                        58      5        91.4%                          0.005   0.945
   ≥60                                         22      2        90.9%                                  
  Grade (among endometrioid adenocarcinomas)                                                           
   1                                           27      1        96.3%                          1.333   0.513
   2                                           25      1        96.0%                                  
   3                                           7       1        85.7%                                  
  Pathological type                                                                                    
   Endometrioid adenocarcinoma                 59      3        94.9%                          3.306   0.069
   Other^\*^                                   21      4        81.0%                                  
  Tumor size                                                                                           
   \<2 cm                                      24      2        91.7%                          2.436   0.296
   2--5 cm                                     38      5        86.8%                                  
   \>5 cm                                      18      0        100.0%                                 
  Myometrial invasion deep                                                                             
   \<1/2                                       53      3        94.3%                          1.715   0.190
   ≥1/2                                        27      4        85.2%                                  
  Cervical invasion deep                                                                               
   \<1/2                                       61      6        90.2%                          0.350   0.554
   ≥1/2                                        19      1        94.7%                                  
  LVSI                                                                                                 
   Yes                                         20      4        80.0%                          3.454   0.063
   No                                          60      3        95.0%                                  
  Surgical method                                                                                      
   Simple hysterectomy                         40      3        92.5%                          0.090   0.764
   Radical hysterectomy                        40      4        90.0%                                  
  Surgical pathway                                                                                     
   Laparotomy                                  44      6        86.4%                          3.564   0.059
   Laparoscopic                                36      1        97.2%                                  
  Lymphadenectomy                                                                                      
   Yes                                         72      5        93.1%                          4.186   0.041
   No                                          8       2        75.0%                                  
  Omentum resection                                                                                    
   Yes                                         6       1        83.3%                          0.567   0.451
   No                                          74      6        91.9%                                  
  Postsurgical treatment                                                                               
   Observation                                 32      1        96.9%                          3.464   0.325
   Chemotherapy                                34      5        85.3%                                  
   Chemotherapy + radiotherapy                 12      1        91.7%                                  
   Endocrine therapy                           2       0        100.0%                                 

\*Serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and mixed cell adenocarcinoma. LVSI: lymphovascular space invasion.

###### 

Multivariate analysis of demographic, surgical, and pathological factors.

![](10.1177_0300060519863190-table4)

  Risk factor                                                                    Hazard ratio (95% CI)   *P* value
  ------------------------------------------------------------------------------ ----------------------- -----------
  Pathological type (endometrioid adenocarcinoma compared withother types^\*^)   0.521 (0.102--2.669)    0.434
  LVSI(no compared with yes)                                                     0.337 (0.068--1.672)    0.183
  Surgical pathway(laparotomy compared with laparoscopic surgery)                4.122 (0.418--40.669)   0.225
  Lymphadenectomy(no compared with yes)                                          1.700 (0.289--9.997)    0.557

\*Serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma, and mixed cell adenocarcinoma. CI, confidence interval, LVSI: lymphovascular space invasion.

Furthermore, there was no significant difference in cancer-related survival rates between the SH and RH groups ([Table 3](#table3-0300060519863190){ref-type="table"}). The 3-year cancer-related survival rates in the SH and RH groups were 94.97% and 92.53%, and the 5-year cancer-related survival rates were 92.40% and 90.03%, respectively. There were no significant differences in cancer-related survival rates between the two groups ([Figure 2](#fig2-0300060519863190){ref-type="fig"}).

![Cancer-related survival curve according to hysterectomy type. There were no significant differences in survival between the SH and RH groups. The 3-year cancer-related survival rates in the SH and RH groups were 94.97% and 92.53% and the 5-year cancer-related survival rates were 92.40% and 90.03%, respectively. SH: simple hysterectomy, RH: radical hysterectomy, Cum survival: cumulative survival, censored: patients lost to follow-up and patients who survived until the end of the study.](10.1177_0300060519863190-fig2){#fig2-0300060519863190}

Perioperative outcomes of SH and RH {#sec11-0300060519863190}
-----------------------------------

In terms of choosing the optimal surgical method for stage II EC, we examined perioperative outcomes and quality of life, in addition to cancer-related survival rates ([Table 5](#table5-0300060519863190){ref-type="table"}). SH was associated with significantly less intraoperative bleeding (mean ±standard deviation: 325.0 ± 307.7 mL vs 625.0 ± 581.4 mL, respectively, *P* = 0.010) and a shorter catheter-indwelling time compared with RH (4.8 ± 3.5 days vs 11.5 ± 3.9 days, *P* \< 0.001). However, there was no significant difference in the length of hospital stay after surgery, hospitalization cost, therapeutic time with antibiotics, or total number of postoperative complications between the two groups.

###### 

Comparison of perioperative situations in patients undergoing simple hysterectomy and radical hysterectomy.

![](10.1177_0300060519863190-table5)

                                          Simple hysterectomy   Radical hysterectomy   *P* value   χ^2^
  --------------------------------------- --------------------- ---------------------- ----------- -------
  Length of postoperative hospital stay   13.5 ± 4.6            15.4 ± 4.8             0.060       
  Hospitalization costs                   22428.1 ± 7654.9      22428.1 ± 12562.0      0.516       
  Hospitalization costs (after 2008)      23115.2 ± 9134.8      27151.1 ± 11432.3      0.283       
  Intraoperative bleeding                 325.0 ± 307.7         625.0 ± 581.4          0.010       
  Therapeutic time of antibiotics         3.4 ± 1.5             3.9 ± 2.0              0.259       
  Time of indwelling catheter             4.8 ± 3.5             11.5 ± 3.9             \<0.001     
  Postoperative complications             5                     4                      0.724       0.125

Moreover, 12.5% (5/40) of patients in the SH group had postoperative complications (postoperative morbidity, n = 3; incision infection, n = 1; pelvic abscess, n = 15), compared with 10.0% (4/40) in the RH group (intestinal obstruction, n = 1; postoperative morbidity, n = 1; *Escherichia coli* infection, n = 1; uroschesis and urinary tract infection, n = 1). There was no significant difference in complication rates between the two groups, but there were more types of complications after RH compared with SH.

Discussion {#sec12-0300060519863190}
==========

Although most women diagnosed with EC present with early-stage disease confined to the uterus, metastatic disease is identified in a significant percentage after comprehensive staging surgery,^[@bibr17-0300060519863190]^ suggesting the need for more radical and thorough surgery in patients with stage II EC. Previous editions of the NCCN and EMSO guidelines recommended RH for clinical stage II EC with suspected gross cervical involvement. However, given the high incidence of sexual dysfunction and poor quality of life following RH, we investigated the possibility of replacing RH with SH in patients with stage II EC.

Several studies found that RH was associated with increased disease-free and overall survival. For example, Sartori et al.^[@bibr10-0300060519863190]^ conducted a retrospective trial of 135 SH and 68 RH procedures for stage II EC and showed that the 5-year (94% vs 79%) and 10-year (94% vs 74%) survival rates were higher in the RH compared with the SH group. Likewise, Cohn et al.^[@bibr11-0300060519863190]^ studied 162 patients with surgical stage II EC and found a significantly better 5-year disease-free survival rate in patients undergoing RH compared with extrafascial hysterectomy (94% vs 76%). In a larger sample size, Cornelison et al.^[@bibr12-0300060519863190]^ based their results on the SEER database, which included 932 patients with stage II EC, and showed that RH was associated with better survival than SH (92.96% vs 84.36%), but there was no significant survival difference between patients with and without radiation in either surgical group.

However, the above-mentioned studies were performed almost 10 years ago, prior to the development of the FIGO 2009 staging system. They therefore included patients with both endocervical glandular involvement (1988 FIGO stage IIA) and cervical stromal invasion (1988 FIGO stage IIB). In addition, the prevalence of laparoscopy and improvements in surgical equipment, environment, and technology may also have increased survival after hysterectomy. Although several studies found no significant improvement in overall survival among patients with EC after laparoscopy compared with laparotomy, ^[@bibr18-0300060519863190],[@bibr19-0300060519863190]^ some reports indicated that the morbidity of hysterectomy has decreased over recent decades.^[@bibr20-0300060519863190][@bibr21-0300060519863190]--[@bibr22-0300060519863190]^ Averette et al.^[@bibr21-0300060519863190]^ demonstrated a continuing trend towards decreasing morbidity and mortality rates after RH in the published literature. Likewise, Benjamin et al.^[@bibr22-0300060519863190]^ reported significant reductions in blood loss, blood transfusions, and hospital stay after hysterectomy between the periods 1980 to 1993 and 1991 to 1993. In addition, advancements in pathological diagnosis and radiological technologies enable the discovery of small parametrial infiltrations in more patients, resulting in more extensive surgeries and thorough treatments and thus decreasing the incidence of misdiagnosed stage II EC and allowing patients to undergo non-radical surgeries.

Several recent studies have shown conflicting results. For example, Takano et al.^[@bibr13-0300060519863190]^ reported on 300 patients with stage II EC who underwent RH, modified hysterectomy, or SH, and indicated that the type of hysterectomy was not a prognostic factor in patients with EC and gross cervical involvement, though perioperative and late adverse events were more frequent in patients treated with RH. Similarly, Ozgul et al.^[@bibr14-0300060519863190]^ conducted a multicenter, retrospective trial in Turkey including 250 patients with stage II EC, of whom 199 underwent SH and the remaining 51 underwent RH. They found that age was the only independent risk factor for overall survival, and the type of hysterectomy had no effect on either disease-free or overall survival. Phelippeau et al.^[@bibr15-0300060519863190]^ analyzed the data for 2886 patients with type 1 FIGO stage II EC from the SEER database. After one-to-two matching, 273 patients who underwent RH and 546 who received SH were included in the statistical analysis, which found no significant difference in 3-year cancer-related survival rates between the two groups (88.7% and 94.1%, respectively).

In the current study, we aimed to determine the survival and perioperative outcomes in patients with stage II EC according to the 2009 FIGO staging system, treated with different types of hysterectomy. We used a case-matched method to avoid any effects of population heterogeneity between the SH and RH groups on the final results. Our results showed that hysterectomy type had no impact on overall survival, although RH could lead to more intraoperative bleeding, a longer catheter-indwelling time, and more complex postoperative complications.

Parametrectomy is the most challenging part of an RH. It is responsible for postoperative urological dysfunction associated with autonomic nerve injury, and the interval before recovery of spontaneous voiding depends on the amount of parametrium removed. This accounts for why patients undergoing RH need a longer catheter-indwelling time than patients who undergo SH.^[@bibr23-0300060519863190],[@bibr24-0300060519863190]^ As shown in the current and previous studies, RH can also lead to significant blood loss and more complex postoperative complications, which in turn prolong hospital stay. ^[@bibr9-0300060519863190],[@bibr13-0300060519863190]^ Furthermore, RH is associated with a high incidence of sexual dysfunction, which may severely reduce the patient's quality of life.^[@bibr8-0300060519863190]^ Indeed, some patients in the current study complained of an unsatisfactory sex life during their telephone follow-up calls.

The above results suggest that reducing the universality of surgery in patients with stage II EC may not only decrease perioperative complications, but may also improve patient quality of life.

The current study had some limitations. We included patients diagnosed with stage II EC from 2000 to 2014, and this long time span may thus have introduced differences in relation to the operative methods, given that perioperative effects were related to the operation environment and technique of the surgeon. In addition, 30 patients were lost to follow-up, which would unavoidably cause some bias. Furthermore, the case-matched method meant that the sample size was relatively small, and investigations in a larger sample could enhance the credibility of these results. Finally, it should be noted that a *P*-value \>0.05 does not necessarily indicate a lack of any difference, and we should learn to embrace uncertainty.^[@bibr25-0300060519863190]^ Thus although our results were most compatible with a lack of any important difference between SH and RH in terms of survival outcomes in patients with stage II EC, it is not possible to make definitive decisions based solely on the *P*-value.

Conclusions {#sec13-0300060519863190}
===========

The results of the current retrospective study suggest that SH has similar survival outcomes to RH in patients with FIGO stage II EC. Furthermore, RH may be associated with more intraoperative bleeding, a longer catheter-indwelling time, and more complex postoperative complications than SH. Further prospective studies with large sample sizes are needed to confirm the outcomes of these two surgical procedures in patients with stage II EC.
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